Unmet challenges in treating hypertension in patients with borderline personality disorder by Roininen, Saara M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Unmet challenges in treating hypertension in patients with borderline
personality disorder
Roininen, Saara M ; Cheetham, Marcus ; Mueller, Beatrice U ; Battegay, Edouard
Abstract: BACKGROUND: Caregivers encounter serious and substantial challenges in managing hyper-
tension in patients with subclinical or clinical borderline personality disorder (BPD). These challenges
include therapeutic conflicts resulting from harmful drug-drug, and drug-disease interactions. Current
guidelines provide no recommendations for concurrent psychotropic and antihypertensive treatment of
hypertensive BPD patients who are at even greater cardiovascular risk. METHODS: We conducted a
systematic literature review to assess the extent of available evidence on prevalence rates, cardiovascular
risk factors, therapeutic conflicts, and evidence-based treatment recommendations for patients with co-
occurring hypertension and BPD. Search terms were combined for hypertension and BPD in PubMed,
MEDLINE, EMBASE, Cochrane, and PsycINFO databases. RESULTS: We included 11 articles for full-
text evaluation and found a very high prevalence of hypertension and substantial cardiovascular risk
in studies on co-occurring BPD and hypertension. However, we identified neither studies on harmful
drug-drug and drug-disease interactions nor studies with treatment recommendations for co-occurring
hypertension and BPD. CONCLUSIONS: Increased prevalence of hypertension in BPD patients, and
therapeutic conflicts of psychotropic agents strongly suggest careful evaluation of treatment strategies
in this patient group. However, no studies or guidelines recommend specific therapies or strategies to
resolve therapeutic conflicts in patients with hypertension and BPD. This evidence gap needs attention
in this population at high risk for cardiovascular disease.
DOI: https://doi.org/10.1097/md.0000000000017101
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-174624
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Roininen, Saara M; Cheetham, Marcus; Mueller, Beatrice U; Battegay, Edouard (2019). Unmet challenges
in treating hypertension in patients with borderline personality disorder. Medicine, 98(37):e17101.
DOI: https://doi.org/10.1097/md.0000000000017101
Unmet challenges in treating hypertension in
patients with borderline personality disorder
A systematic review
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Abstract
Background: Caregivers encounter serious and substantial challenges in managing hypertension in patients with subclinical or
clinical borderline personality disorder (BPD). These challenges include therapeutic conﬂicts resulting from harmful drug–drug, and
drug–disease interactions. Current guidelines provide no recommendations for concurrent psychotropic and antihypertensive
treatment of hypertensive BPD patients who are at even greater cardiovascular risk.
Methods: We conducted a systematic literature review to assess the extent of available evidence on prevalence rates,
cardiovascular risk factors, therapeutic conﬂicts, and evidence-based treatment recommendations for patients with co-occurring
hypertension and BPD. Search terms were combined for hypertension and BPD in PubMed, MEDLINE, EMBASE, Cochrane, and
PsycINFO databases.
Results: We included 11 articles for full-text evaluation and found a very high prevalence of hypertension and substantial
cardiovascular risk in studies on co-occurring BPD and hypertension. However, we identiﬁed neither studies on harmful drug–drug
and drug–disease interactions nor studies with treatment recommendations for co-occurring hypertension and BPD.
Conclusions: Increased prevalence of hypertension in BPD patients, and therapeutic conﬂicts of psychotropic agents strongly
suggest careful evaluation of treatment strategies in this patient group. However, no studies or guidelines recommend speciﬁc
therapies or strategies to resolve therapeutic conﬂicts in patients with hypertension and BPD. This evidence gap needs attention in
this population at high risk for cardiovascular disease.
Abbreviations: ACC = American College of Cardiology, AHA = American Heart Association, BPD = borderline personality
disorder, HPA = hypothalamic-pituitary-adrenal stress system.
Keywords: borderline personality disorder, drug–disease interactions, drug–drug interactions, hypertension, treatment strategies
1. Introduction
Hypertension increases the risk for cardiovascular morbidity and
mortality, and affects almost one-third of all people worldwide.[1]
Prevalent psychiatric comorbidities such as depression, anxiety
disorders, psychosis, and borderline personality disorder (BPD)
elicit challenges in the treatment of hypertension and worsen
outcomes.[2] Over 40% of patients in internal medicine
emergency departments have hypertension and up to 10% of
patients in psychiatric emergency departments have BPD
suggesting an overlap of these disorders.[3,4] Speciﬁcally, 9%
to 27% of patients with agitation in emergency departments are
diagnosed with BPD.[5] Unfortunately, readmission rates are high
for hypertension patients with psychiatric comorbidities, espe-
cially with personality disorders.[6]
Borderline personality disorder causes impulsivity, disturbed
interpersonal interrelatedness, warped cognitive perceptions
anger, anxiety, depression, tension, and a chronic feeling of
emptiness.[7,8] Prevalence of BPD in the general population varies
between 0.5% and 4%.[9–12] Persons with BPDmake up to 6%of
patients in primary care,[13] 25% of psychiatric outpatients, and
43% of psychiatric inpatients.[8,14] Unhealthy life styles, and
lower socioeconomic status in BPD associate with poorer somatic
health.[2,15] Comorbidities emerge earlier in persons with
BPD,[16] and these may in turn worsen BPD. In addition,
comorbidities increase health care utilization, prolong hospital-
izations, and lead to a higher readmission rate, higher costs, and
premature mortality.[17,18] BPD patients, even undiagnosed ones,
often use mental and somatic health care in excessive, disrupted,
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uncontrolled and ineffective patterns and trajectories.[12] Contact
with health care services occurs predominantly in acute crisis.[7]
BPD-related trauma, drugs, self-harm, and suicide lead to
frequent hospital readmissions.[19,20]
BPD predisposes patients to short-term worsening of existing
hypertension due to autonomic stress dysregulation and the
activation of the hypothalamic-pituitary-adrenal (HPA) stress
system.[21–23] Other predisposing factors include nonconcord-
ance with antihypertensive therapy, and treatment plans.
Drugs used for the treatment of hypertension or BPD may
potentially worsen the other condition. Psychotropic agents used
for treating BPD symptoms increase the risk of cardiovascular
disorders.[24] Prescription rates for psychotropic agents are high
for persons with BPD,[9,10] with 54% BPD patients having ≥ 3
psychotropic agents concomitantly and 80% ≥ 2 respectively.[25]
Chanen et al[7] reported that doctors prescribed psychotropic
agents to 78% of BPD patients for more than 75% of the time
over a 6-year period and polypharmacy occurred in 37% of these
patients. In addition to drug–drug and drug–disease interactions
between psychotropic agents, interactions also occur between
psychotropic and antihypertensive agents.[24,26]
The prevalence of hypertension is higher in BPD patients than
in the general population,[2] and hypertension may be under-
diagnosed in this population. Antihypertensive drugs have
neuropsychiatric side effects such as fatigue and depression
and psychotropic agents have long-term cardiovascular side
effects such as hypertension, weight gain, and metabolic
changes.[27–30] Treatment of hypertensive BPD patients merits
hence careful attention for such interactions.
The ACC/AHA et al guideline 2017 for themanagement of high
blood pressure recommends caution in prescribing psychotropic
agents to patients with hypertension because of their potential
detrimental cardiovascular side effects.[31] Furthermore, drug
afﬁnities for histamine, dopamine serotonin, and muscarinic
receptors are closely linked to cardiovascular risk accumulation,
and patients with a history of heart disease, arrhythmia, or
syncope, or family history of prolonged QT syndrome on early
sudden death should not receive QT-prolonging antipsychotic
agents.[26] However, to our knowledge, no guidelines address in
detail the treatment of hypertension in patients with BPD.
Given the lack of guidelines for concurrent psychotropic and
antihypertensive treatment of hypertensive BPD patients, we
systematically reviewed the literature to assess currently available
evidence on the prevalence rate of hypertension and BPD, and the
cumulated cardiovascular risk of these 2 conditions in conjunc-
tion. We also systematically reviewed literature on potential
therapeutic conﬂicts (i.e., harmful drug–drug and drug–disease
interactions) and evidence-based therapeutic strategies for
hypertension treatment in patients with BPD.
2. Methods and materials
2.1. Literature search and screening
We performed a comprehensive qualitative systematic literature
search following the PRISMA guideline 2009[32] on all
publications until September 13, 2018, through the PubMed,
MEDLINE, EMBASE, Cochrane, and PsycINFO databases
(Supplemental Table 1, http://links.lww.com/MD/D230). We
used search terms (“borderline personality”) AND (“hyperten-
sion”) including variations of the 2 terms (Table 1). We kept the
search terms for the database queries as broad as possible to
ensure maximal coverage of the literature. A Boolean operator
“AND” combined the search terms through abstracts, keywords,
and titles and free text. Consequently, we merged the selected
articles of the 5 databases and subsequently removed duplicates
by using EndNote X8 (Thomson Reuters). Ethical approval was
not required since no patient-related data was acquired or
analyzed in conducting this systematic review.
2.2. Selection criteria
Selection criteria included full-text articles written in English
relating to both of these disorders and their respective or
combined management (Table 1). We excluded articles on
nonhumans and articles without abstracts. Since our focus was
on adult patients, we excluded individuals under 18 years of age.
We excluded also pregnant women because hormonal changes
relating to pregnancy might transiently alter the psychiatric
diseases and because we aimed to focus on the combination of
long-term forms of BPD and hypertension. We also excluded
comments, letters, and case studies. For completeness, it is
however worth noting that the all-inclusive BPD- and hyperten-
sion-related search terms in this study did not generate any
literature on individuals under 18 years of age, or on pregnant
women who met the criteria for inclusion in the subsequent steps
of this systematic review.
3. Results
3.1. Identiﬁcation of publications
We identiﬁed 195 publications by searching for BPD and
hypertension using PubMed, EMBASE, MEDLINE, Cochrane
Library, and PsycINFO databases. After removal of duplicates,
Table 1
Search terms used in the systematic literature search for detection of co-occurrence of BPD and hypertension.
“borderline personality” AND (“disorder” OR “disease” OR “patient” OR “patients” OR “syndrome” OR “symptom” OR “symptoms” OR “illness” OR “trait” OR “traits” OR
“features”)
OR “undetected” OR “undiagnosed” OR “underdiagnosed” OR “missed diagnosis” AND
“borderline personality” AND (“disorder” OR “disease” OR “patient” OR “patients” OR “syndrome” OR “symptom” OR “symptoms” OR “illness” OR “trait” OR “traits” OR
“features”)
AND
“hypertension” OR “acute hypertension” OR “chronic hypertension” OR “hypertensive” AND (“emergency” OR “crisis” OR “patient” OR “patients” OR “urgency” OR “symptom”
OR “symptoms”) OR “blood pressure” OR “high blood pressure” or “elevated blood pressure”
OR “undetected” OR “undiagnosed” OR “underdiagnosed” OR “missed diagnosis” AND
“hypertension” OR “acute hypertension” OR “chronic hypertension” OR “hypertensive” AND (“emergency” OR “crisis” OR “patient” OR “patients” OR “urgency” OR “symptom”
OR “symptoms”) OR “blood pressure” OR “high blood pressure” or “elevated blood pressure”
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we included the 143 remaining publications in a 2-step evaluation
procedure. In the ﬁrst step, we evaluated the abstracts. Two
independent authors, SMR and MC, selected abstracts for
inclusion separately before discussing their inclusion together.
No disagreements emerged. The selection of abstracts was based
on the following criteria: the abstract contained at least 1 BPD-
related term such as “borderline personality” and at least 1
hypertension-related term such as “high blood pressure,” as
shown in Table 1. The ﬁrst step resulted in 24 articles that
included both hypertension- and BPD-related terms in the
abstract (Table 2).[15,16,33–54]
In the second step, we evaluated the full texts of these 24
articles for pharmacological treatment of either hypertension,
BPD or both conditions and for drug–drug and drug–disease
interactive effects. Of these articles, 11 were included in the
analysis (Fig. 1, Table 3).[15,16,33–35,37,40,43,47,49,53]
3.2. Prevalence of concurrent hypertension and BPD
Prevalence of concurrent hypertension and BPD varied between
6.7% and 46.7% in 5 studies that reported prevalence
rates.[16,33,34,37,40] Among studies on BPD patients, patients
with an insufﬁciently controlled but treated BPD and BPD with
obesity, had a signiﬁcantly higher prevalence of hypertension
compared with the control group, respectively (12.5% vs. 4.2%,
P= .023,[16] and 12.2% vs. 4.2%, P< .05[37]). Obese BPD
patients who were to undergo bariatric surgery had a 46.7%
prevalence rate of hypertension.[40] A signiﬁcantly higher
prevalence of hypertension in BPD patients was also reported
in 2 national longitudinal studies comparing BPD patients with
other study participants (6.4% vs. 3.7%, P< .001[33] and 28.2%
vs. 25.4%, P< .001[34], respectively). In 4 of these articles, BPD
and hypertension were diagnosed by a physician,[16,33,37,40] and
in one, both conditions were self-reported.[34] In summary, the
rate of hypertension is higher among BPD patients, especially in
patients with an active BPD.
3.3. Risk of cardiovascular disorders and screening for
risk factors
BPD associates with an elevated risk of somatic, mainly
cardiovascular morbidities in 3 population-based analy-
ses.[15,33,34] After adjusting for age, sex, and confounders,
Moran et al[15] reported increased risk of strokes and ischemic
heart disease (OR: 8.5; 95% CI, 1.0–72.8 and OR: 7.2; 95% CI,
2.1–24.3, respectively) among BPD patients when comparedwith
the general population without personality disorders. Chen
et al[33] reported a signiﬁcantly elevated rate of diabetes (4.2% vs.
1.9%, P< .001), dyslipidemia (6.2% vs. 3.5%, P< .001), and
ischemic heart disease (2.0% vs. 0.5%, P< .001), and El-
Gabalawy et al[34] reported signiﬁcantly increased rates of
diabetes (9.3% vs. 8.1%, P< .001) and obesity (33.6% vs.
27.1%, P< .001) in BPD patients. In BPD cohort studies,
insufﬁciently controlled but treated PBD patients and obese BPD
patients had more health problems compared with BPD patients
without combination of these particular comorbidities.[16,37] The
rate of diabetes and chronic back pain was signiﬁcantly increased
in insufﬁciently controlled but treated PBD patients (10.9% vs.
1.5%, P= .028 and 62.5% vs. 38.5%, P< .001) compared with
remitted BPD patients.[16] The rate of diabetes and asthma was
Table 2
Articles (n=24) included after ﬁrst evaluation step.
Authors Title
Chen, M-H, et al. (2017) Risk of stroke among patients with borderline personality disorder: A nationwide longitudinal study.
Eddie, D (2018) Borderline personality disorder, co-occurring substance use, and autonomic dysregulation.
El-Gabalawy, R, et al. (2010) Comorbidity and associated severity of borderline personality disorder and physical health conditions in a nationally
representative sample.
Elgarov, AA, et al. (2015) Epidemiology of ischemic heart disease and atherosclerosis risk factors in imprisoned men.
Eslami-Shahrbabaki, M, et al. (2015) A Study of the Prevalence of Psychiatric Disorders in Patients with Methamphetamine-Induced Psychosis.
Frankenburg, FR, et al (2004) The association between BPD and chronic medical illnesses, poor health-related lifestyle choices and costly forms of health
care utilization.
Frankenburg, FR, et al (2006) Obesity and obesity-related illnesses in borderline patients.
Franklin, C, et al. (2015) Ulcerated necrobiosis lipoidica as a rare cause for chronic leg ulcers: Case report series of ten patients.
Galle, F, et al. (2015) Does Post-operative Psychotherapy Contribute to Improved Comorbidities in Bariatric Patients with Borderline Personality
Disorder Traits and Bulimia Tendencies? A Prospective Study.
Geiss, L, et al. (2018) Reduced autonomic modulation of blood pressure and shifted sympatho-vagal balance in borderline personality disorder.
Golubev, MV, et al. (1998) The efﬁcacy of psychotherapy with biofeedback in the rehabilitation of hypertension patients.
Grove, JL, et al. (2017) Borderline personality features, interpersonal correlates, and blood pressure response to social stressors: Implications for
cardiovascular risk.
Grove, JL, et al. (2014) BPD symptomatology and risk for cardiovascular disease: Heightened physiological reactivity as a mechanism.
Ladea, M, et al. (2010) Acute psychotic disorder due to the use of ethnobotanical substances.
Liebowitz, MR, et al. (1990) Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
Lobbestael, J, et al. (2009) Effects of induced anger in patients with antisocial personality disorder.
Moran, P, et al. (2007) Personality disorder and cardiovascular disease: results from a national household survey.
Nct (2013) Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder.
Philipsen, A, et al. (2004) Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder.
Reinagel-Canarelli, DC (2018) Dive reﬂex induction: Regulating emotion in individuals with eating disorders.
Samardzic, R (2012) Posttraumatic depression: Issue of comorbidity.
Schmahl, C G, et al. (2002) Individual differences in psychophysiological reactivity in adults with childhood abuse.
Schmahl, CG, et al. (2004) Psychophysiological reactivity to traumatic and abandonment scripts in borderline personality and posttraumatic stress
disorders: a preliminary report.
Shankar, K, et al. (2014) Eating behaviors in borderline personality disorder and its association with metabolic abnormalities.
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signiﬁcantly increased among obese BPD patients compared with
nonobese BPD patients (10.8% vs. 1.1%, P= .003 and 47.3% vs.
19.5%, P< .001).[37] Moran et al[15] suggested that BPD patients
could potentially beneﬁt from a prevention strategy for
cardiovascular diseases including hypertension. El-Gabalawy
et al[34] recommended that BPD patients should be carefully
screened and treated for their diverse somatic health problems.
3.4. Changes in blood pressure levels among BPD
patients
Psychological studies analyzing the effects of autonomic nervous
system (ANS) activation in BPD patients showed contradicting
results. One study demonstrated distinct differences in the
sympathetic activation of the ANS in BPD patients.[35] This was
shown by signiﬁcant increases in skin conductance and heart rate
for picture stimuli among BPD patients compared with controls.
An analysis of BPD featured patients (n=188) from Grove
et al[43] reported elevated diastolic blood pressure levels in BPD-
featured patients while listening and talking to a hostile partner
(b=0.16, t(142)=1.95, P= .05, and b=0.18, t(142)=2.27,
P= .03, respectively). Contrary to these ﬁndings, Schmahl et al[53]
reported a lower ANS response to stressors in BPD patients.
These patients were, however compared with posttraumatic
disorder patients. Several articles stated that the responsivity of
BPD patients to different stressors remains an unresolved
debate,[47,53,55] and may potentially predict increased risk for
cardiovascular disorder development.[43]
3.5. Strategies for treatment of concurrent hypertension
and BPD
Clear guidelines for the treatment of co-occurring hypertension
and BPD are still missing. However, some preliminary steps have
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been taken. An analysis on the effects of dialectical behavioral
therapy (DBT) among bariatric BPD patients resulted in a
signiﬁcant reduction of hypertension (P= .02, 25 patients
remitted from hypertension), and other somatic comorbidities
in patients who had undergone dialectical psychotherapy for 12
months, hence suggesting DBT as a potential aid for reducing
somatic comorbity burden on this speciﬁc patient group.[40] One
analysis on adverse inner tension in BPD patients (n=22)
demonstrated Clonidine to signiﬁcantly lower blood pressure
within 2 hours during an acute self-injurious situation.[49]
However, this study did not report long-term effects of Clonidine
on blood pressure levels. Based on the nascent literature, good
psychiatric care positively affects treatment results of hyperten-
sion and other somatic comorbidities in BPD patients.[16,40,56]
3.6. Description of drug–drug or drug–disease interactions
of co-occurring hypertension and BPD
Despite its importance, drug–drug or drug–disease interactions of
co-occurring hypertension and BPD, and its therapy were not
speciﬁcally addressed in any of these articles.
4. Discussion
We have conducted a systematic literature review to assess
evidence of the co-occurrence of hypertension and BPD, the
associated combined cardiovascular risk, harmful therapeutic
conﬂicts, and recommendations or therapeutic strategies for
managing patients with hypertension and BPD. We summarized
our main ﬁndings as key messages (Table 4). To our knowledge,
this is the ﬁrst such review.
The choice of search terms ensured an all-inclusive search of
literature relating to hypertension and BPD. The combined use of
the databases (PubMed, MEDLINE, EMBASE, Cochrane, and
PsycINFO) warranted coverage of up to 97% of available
publications.[57] Of the initially identiﬁed 143 articles, 11 were
included in the analyses. These studies conﬁrmed the increased
rates of hypertension and cardiovascular risk factors among BPD
patients. Surprisingly, none of these publications clearly reported
the evidence of therapeutic conﬂicts (i.e., drug–drug or drug–
disease interactions), or addressed the treatment strategies of
patients with hypertension and BPD. Moreover, none of these
publications referred to treatment recommendations for this
particular patient group.
In cohort studies, the level of hypertension was signiﬁcantly
higher in BPD patients than in control patients.[16,33,34,37,40]
Three studies reported a signiﬁcantly earlier onset of hyperten-
sion in BPD patients.[16,33,34] Chen et al showed BPD to associate
with strokes at a signiﬁcantly higher rate and younger age. In this
study, comorbidity burden was also associated with an increased
patient suffering and a poorer quality of life.[16] Other screened
studies showed an association of BPD with metabolic syndrome
and cardiovascular risk factors.[58–61] Furthermore, 6 studies
recommended a careful screening of BPD patients for diverse
physical health conditions, especially for cardiovascular disor-
ders in general,[34,44,58–60] 3 studies recommended treatment of
these somatic comorbidities.[15,34,58] All these described results
align with the ﬁnding of a suicidality-independent reduction of
life-expectance of BPD patients by 9 to 13 years due to somatic
comorbidity.[62]
A review of drug–drug interactions in 1995 already underlined
the importance of risk assessment of concurrently prescribed
antipsychotic and antihypertensive agents.[63] This suggestion
extends to almost all hypertension patients with BPD, since most
of these are under psychotropic medication.[9,10,64] In our study,
we found no publications on harmful drug–drug or drug–disease
interactions within or between psychotropic and antihyperten-
sive agents in patients with hypertension and BPD. This is even
more surprising as the co-occurrence of the 2 conditions is likely
to be relatively prevalent in the population.
The lack of data in this patient population may be partially due
to the fact that physicians prescribe psychotropic agents off-label
for BPD patients. A few studies report from a long-term use of
approximately 3 different psychotropic agents per BPD pa-
tient,[4,25] even though recommendations advise short-term
single-drug therapy as a second-line treatment subsequent or
adjunct to psychotherapy.[10,65,66] Additional comorbidities in
these patients (e.g., diabetes and depression) and therefore the
lack of homogeneous patient samples complicate the assessment
of interactions between drugs used for hypertension and BPD
treatment.[67,68] Heterogeneity in methodology and outcome
measures across clinical trials also hinder assessment of treatment
efﬁcacy in BPD patients.[69,70]
Theoretically, potential drug–drug or drug–disease interac-
tions between and within the groups of antipsychotic and
antihypertensive agents could be collated from known databases
in order to characterize the clinical relevance and severity of these
therapeutic conﬂicts.[71] However, data on prescription practices
in hypertension patients with BPD is lacking,[72] and may not
speciﬁcally apply to these patients who tend to use medications in
more disordered manners than average hypertension patients.
Hypertension studies also exclude patients with severe psychiat-
ric morbidities due to noncompliance and potential medication
misuse.[73,74] Characterization of potential therapeutic conﬂicts
for these patients is, hence, needed.
Harmful drug–drug and drug–disease interactions occur
especially within but also between the groups of psychotropic
and antihypertensive agents.[63] As an example of a drug–drug
interaction between 2 psychotropic agents, the antipsychotic
agent Quetiapine might increase the central-nervous toxicity and
induce QT-prolongation effect of an antidepressant agent
Citalopram.[71] The antipsychotic Clozapine induces weight gain
for 4% to 31% of the patients predisposing patients with
hypertension, representing a drug–disease interaction.[71]
The interaction of lithium and angiotensin-converting enzyme
(ACE) inhibitors illustrates a drug–drug interaction between
psychotropic and antihypertensive agents. Lithium is used in BPD
patients for treatment of self-harming behavior and mood
swings,[64,75] whereas ACE inhibitors form the backbone for
treatment of hypertension.[31,76] Concomitant use of these
pharmacological agents may increase the serum concentration
level of lithiumtoa toxic level and cause life-threateningneurologic
and cardiac symptoms including lethargy and arrhythmias.[77]
Table 4
Key messages.
Hypertension and BPD co-occur at a higher rate compared with control groups.
Patients with hypertension and BPD have an increased risk of cardiovascular
morbidity and mortality.
Therapeutic conﬂicts between pharmacological agents warrant constant evaluation.
Guidelines/guidance and data for managing hypertension in BPD patients are needed.
BPD may underlie hypertension patients with high health care utilization rates.
BPD=borderline personality disorder.
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Psychotropic agents consistently prescribed for BPD in the
long-term predispose BPD patients to drug–disease interactions
that elevate the risk for hypertension and other cardiovascular
disorders, such as weight-gain, diabetes, and increased lipid
levels.[24,30,78] This applies for almost all psychotropic agents and
their use should therefore be controlled and reevaluated
regularly. Physicians should also be aware that antihypertensive
agents could induce harmful psychiatric effects. For example,
hydrochlorothiazide and other diuretics have been shown to
cause anxiety, depressiveness, aggressiveness, and psychotic
symptoms.[27,28] These symptoms may at least categorically
overlap with and mimic BPD symptoms, and potentially hamper
the accurate diagnosis of BPD.
Whether these potential conﬂicts translate into adverse
outcomes in everyday medical practice remains to be investigat-
ed. It is also unclear whether drug management in patients with
hypertension and BPD differs depending on the setting for
example between internist and psychiatric emergency depart-
ments or different regions.
Emergency departments experience frequent health service use
by BPD patients in periods of acute crisis due to self-harm and
suicidal attempts.[79,80] Even in the absence of crisis, demands
and pressures on patient–doctor interactions in hypertension
patients with BPD may be overwhelming because of aggres-
siveness, impulsivity, anxiety, volatility, substance abuse, and
poor adherence with scheduling or drug treatment.[4,79–84] This
may inﬂuence diagnosis, therapy implementation, and drug
management.[5,85–87]
Accurate diagnosis is essential for efﬁcient management of
BPD,[7,12,14] and failure to detect BPD could lead to ineffective or
potentially harmful treatments.[88] It is unclear, whether or how
many hospitalized patients remain undetected for both hyper-
tension and BPD. Our systematic search showed this, since the
addition of search terms for undetected diagnosis for hyperten-
sion and BPD did not produce additional results (Supplemental
Table 1, http://links.lww.com/MD/D230). In hypertension,
major causes for underdiagnosis include poor awareness and
lack of symptoms,[1,89,90] whereas underdiagnosis in BPD likely
results in overlap with other psychiatric disorders such as bipolar
disorder and depression.[12,82,83,91] Stigma of the problematic
diagnosis of BPD[62,92] probably also cautions physicians to give
this diagnosis.[93]
BPD patients utilize healthcare, especially in the times of acute
crisis.[19,20] Hypertension patients recurrently visiting psychiatric
emergency departments should be screened for personality
disorders.[6] Still, more data is needed on the prevalence and
health service utilization patterns of hypertensive BPD patients
during and outside times of BPD-related crisis in internist and
psychiatric departments. Long-term polypharmacy of these
patients demands clariﬁcation in outpatient settings between
antihypertensive and psychotropic agents as well as between
agents within these 2 medication groups. Cross-disciplinary
expert opinion could be used for collecting guidance in situations
with limited evidence-base. Moreover, substantial improvement
in care for these patients in fragmented health care systems is
needed, as this may lower adherence rates to diagnosis and
therapy in both disorders.[1,94]
Physicians should be aware of the possibility of BPD in
hypertension patients heavily utilizing healthcare. Due to the high
prevalence and medication-induced risk of cardiovascular
disorders in BPD and the potential harmful therapeutic conﬂicts
within and between psychotropic and antihypertensive agents,
physicians need to pay special attention when treating BPD
patients, especially in conjunction with hypertension.
5. Conclusions
In summary, we have identiﬁed 24 articles for full-text
evaluation, of which 11 were included in the analysis. The
prevalence of hypertension and especially the risk of early onset
cardiovascular disorders are substantially increased in BPD
patients due to mechanisms within BPD (e.g., HPA-dysfunc-
tion), and to the multiple long-term psychotropic medication of
BPD patients (mean of 2.8 drugs). No article or guideline
speciﬁcally examined effects of pharmacological treatment or
addressed potential therapeutic conﬂicts in managing hyper-
tension in patients with BDP. The lack of treatment
recommendations highlights the importance of identifying
evidence gaps in BPD.[95] The reported ﬁndings suggest that
screening for hypertension in BPD patients is needed, and that
BPD should be considered in patients with nonresponsive
hypertension.
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